Camostat and E-64d need to be fast-tracked for clinical trials
These two compounds together form a synergistic blockade of the ability of SARS-CoV-2 to invade human cells (prophylaxis; per the paper in the Cell journal). If side-effects can be rapidly identified and minimal, it could be good bridge until a vaccine is developed (2 years+, high probability of yearly/semi-annual recurrent epidemics). Camostat Mesylate / Camostat / 59721-29-8 - 100-200 mg p.c. (300-600 mg/daily) - Used in Japan for postoperative reflux esophagitis & acute chronic pancreatitis E-64d / Aloxistatin / Loxistatin / EP-453 / 88321-09-9 - Possibly 100-150 mg p.c. (300-450mg/daily) - May increase risk of bleeding / bleeding strokes / reduce clotting / thin the blood - Prices of this compound are currently very high but would hopefully reduce with scale and local synthesis 0 comments on Hacker News.
These two compounds together form a synergistic blockade of the ability of SARS-CoV-2 to invade human cells (prophylaxis; per the paper in the Cell journal). If side-effects can be rapidly identified and minimal, it could be good bridge until a vaccine is developed (2 years+, high probability of yearly/semi-annual recurrent epidemics). Camostat Mesylate / Camostat / 59721-29-8 - 100-200 mg p.c. (300-600 mg/daily) - Used in Japan for postoperative reflux esophagitis & acute chronic pancreatitis E-64d / Aloxistatin / Loxistatin / EP-453 / 88321-09-9 - Possibly 100-150 mg p.c. (300-450mg/daily) - May increase risk of bleeding / bleeding strokes / reduce clotting / thin the blood - Prices of this compound are currently very high but would hopefully reduce with scale and local synthesis
These two compounds together form a synergistic blockade of the ability of SARS-CoV-2 to invade human cells (prophylaxis; per the paper in the Cell journal). If side-effects can be rapidly identified and minimal, it could be good bridge until a vaccine is developed (2 years+, high probability of yearly/semi-annual recurrent epidemics). Camostat Mesylate / Camostat / 59721-29-8 - 100-200 mg p.c. (300-600 mg/daily) - Used in Japan for postoperative reflux esophagitis & acute chronic pancreatitis E-64d / Aloxistatin / Loxistatin / EP-453 / 88321-09-9 - Possibly 100-150 mg p.c. (300-450mg/daily) - May increase risk of bleeding / bleeding strokes / reduce clotting / thin the blood - Prices of this compound are currently very high but would hopefully reduce with scale and local synthesis 0 comments on Hacker News.
These two compounds together form a synergistic blockade of the ability of SARS-CoV-2 to invade human cells (prophylaxis; per the paper in the Cell journal). If side-effects can be rapidly identified and minimal, it could be good bridge until a vaccine is developed (2 years+, high probability of yearly/semi-annual recurrent epidemics). Camostat Mesylate / Camostat / 59721-29-8 - 100-200 mg p.c. (300-600 mg/daily) - Used in Japan for postoperative reflux esophagitis & acute chronic pancreatitis E-64d / Aloxistatin / Loxistatin / EP-453 / 88321-09-9 - Possibly 100-150 mg p.c. (300-450mg/daily) - May increase risk of bleeding / bleeding strokes / reduce clotting / thin the blood - Prices of this compound are currently very high but would hopefully reduce with scale and local synthesis
Hacker News story: Camostat and E-64d need to be fast-tracked for clinical trials
![Hacker News story: Camostat and E-64d need to be fast-tracked for clinical trials]()
Reviewed by Tha Kur
on
March 11, 2020
Rating:
No comments: